Markets
Corporate CEO's Speak At The Hill & Valley Forum On Capitol Hill
Palantir CEO Alex Karp (Kevin Dietsch/Getty Images)

Why Palantir has been the single best Trump trade

The politically connected AI and defense software company has been raking in contracts under the Trump administration.

Matt Phillips

Reporters with The New York Times laid out the growing scope of Palantir’s work with the federal government under the Trump administration, noting that the US has paid Palantir $113 million since President Trump took office, including funds from existing and new contracts (but not including the nearly $800 million contract expansion the Department of Defense awarded last week).

The Friday report sheds new light on the performance of Palantir shares in the Trump 2.0 era.

The stock has been, by far, the best performer among the so-called Trump trades, a group of companies that soared after Donald Trump defeated Joe Biden in 2024, as traders bet that the companies would derive some sort of benefit under the incoming administration.

The bet traders were making on some of these companies — like Taser maker Axon and private prison and deportation contractor GEO Group — was fairly straightforward, as Trump’s law-and-order rhetoric suggested he would prioritize deportations and law enforcement, channeling more government money toward their services.

But for some of the other entities that surged on the election, the potential benefits were a bit more murky.

After all, why would EV maker Tesla jump on the election of Trump, who signaled he wanted to phase out federal programs crucial to the company, except for the notion that the company would somehow benefit from CEO Elon Musk’s relationship with Trump?

Nobody on Wall Street would say it out loud. But a key element of the “Trump trades” was basically the pricing-in of political favors and preferential treatment — less politely put, corruption — benefiting companies like Tesla, which is both run by a staunch political ally and a former de facto member of the administration and reliant on federal tax credits and other incentives to sell its cars.

Palantir falls into this category, too. The company was cofounded 22 years ago by Peter Thiel, who, like fellow PayPal founder Elon Musk, is a politically active billionaire tech oligarch from South Africa. He is also the chairman and largest individual shareholder in Palantir, holding some $9 billion worth of Class A shares.

While Thiel has had an on-again, off-again relationship with Trump, he’s been instrumental in the business and political career of Vice President JD Vance, who worked at one of Thiel’s investment funds, and then was partially backed by Thiel when he started his own fund. Thiel also donated $15 million to Vance’s successful effort to win a Senate seat in Ohio.

Of course, all of Palantir’s recent performance can’t be linked to Trump — its focus on AI software is near the epicenter of some of the hottest trends on Wall Street. And the company has been a government contractor for over a decade, before Trump was in the White House.

But from a business perspective, Palantir remains reliant on US federal government spending, as the US is its single largest client.

The market understands just how important Uncle Sam’s relationship is to Palantir. Remember, it was rumors about deep cuts to defense spending — which ultimately proved incorrect — that cratered the company’s shares back in February.

But if The New York Times’ reporting is any indication, Palantir’s business with Uncle Sam is now booming, suggesting that traders betting on companies with cozy ties to Trump were seeing the situation clearly. And Palantir is flirting with a new record high on Friday.

More Markets

See all Markets
markets

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.